Acelyrin’s IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO

Ace­lyrin said Mon­day that its lead drug izok­ibep failed to meet the pri­ma­ry end­point in a Phase IIb/III tri­al in pa­tients with hidradeni­tis sup­pu­ra­ti­va — a chron­ic in­flam­ma­to­ry con­di­tion that caus­es painful nod­ules and ab­scess­es to form un­der the skin.

It’s the Los An­ge­les biotech’s first big clin­i­cal read­out since it went pub­lic in May, and the news was bru­tal to its shares $SLRN — they fell 64% in af­ter-hours trad­ing Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.